ANEW Medical (WENA) said Thursday it has partnered with researchers at Japan's Okinawa Research Center for Longevity Science for the development of its Klotho gene therapy in reducing age-related diseases.
Okinawa is among a set of global "Blue Zones" with high numbers of people who live to high ages and remain in good health.
ANEW said preliminary data suggests that the alpha-Klotho version of the human Klotho gene and its secreted alpha-Klotho protein isoform may contribute to long lifespans and protection against diseases such as Alzheimer's Disease. The company is developing a portfolio of therapies targeting the gene.
Price: 3.4200, Change: -0.20, Percent Change: -5.52